Blogs & News
IntoCell and Xcellon Biologics Partner to Expand Access to Next-Generation ADC Technologies
- Press Release
Xcellon Biologics partners with IntoCell to expand linker-payload toolbox
Antibody Drug Conjugate CDMO Xcellon partners with Invenra
- Press Release
Invenra’s multispecific antibody platforms, together with Xcellon’s bioconjugation and manufacturing expertise, are advancing the development of complex biologics.
TEDCO Equitech Growth Fund awarded Xcellon Biologics
- News
Xcellon aligns with Maryland's TEDCO EGF for future biologics development and manufacturing.
From Global Pharma to Maryland’s Next-Gen CDMO: Yuk Chun Chiu’s Vision for Xcellon Biologics
- News
BioBuzz interviewed with Yuk Chun Chiu, Xcellon's COO on the vision and journey of the company
Modular Fc Glycan Conjugation: Unlocking Next-Generation Antibody Therapeutics
- Blog
Xcellon’s Fc glycan conjugation platform delivers site-specific, uniform, and stable antibody conjugates for next-gen therapeutics.
Upcoming Events
Xcellon is sponsoring World ADC 2025
Xcellon Biologics is proud to sponsor the World ADC 2025. Come visit our booth and see our latest development in conjugation technologies and gene to IND service offerings!
- 11/03/2025
- — 11/06/2025
Partner
With Us
Partner With Us
Xcellon Biologics is backed by successful biotech entrepreneurs and professionals from top pharmaceutical and CDMO companies including Lonza, Abzena, Amgen, MedImmune, AstraZeneca, BioNTech, Seattle Genetics, and Immunomedics.
We collaborate with leading innovators and global partners to accelerate biopharmaceutical breakthroughs while maintaining the highest quality and regulatory standards.
